Literature DB >> 25295435

Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.

Chun-Yuan Lin1, Guochuan E Tsai, Hong-Song Wang, Yu-Hsin Wu, Chin-Chih Chiou, Vivian Y Wu, Hsien-Yuan Lane.   

Abstract

OBJECTIVE: Previous studies suggested that antidepressants augmented with second-generation antipsychotics (SGAs), including aripiprazole, olanzapine, quetiapine, and risperidone, resulted in better treatment response or higher rates of remission in patients with major depressive disorder (MDD). However, population-based study on SGA augmentation for patients with MDD remains limited. The purpose of this study was to investigate the effectiveness of SGA augmentation for treatment of MDD using the National Health Insurance Research Database in Taiwan.
METHOD: The subjects were patients with MDD (ICD-9-CM code: 296.2 and 296.3) who were initially admitted to psychiatric inpatient settings for the first time between January 1, 1996, and December 31, 2007, and could be tracked until December 31, 2011. To assess the treatment effect of SGA augmentation, 993 MDD patients who received aripiprazole, olanzapine, quetiapine, or risperidone augmentation treatment for 8 weeks or more were included in this 1-year mirror-image study. Outcome measures included length of psychiatric hospitalization and number of psychiatric admissions and emergency room (ER) visits.
RESULTS: After patients received SGA augmentation treatment, key psychiatric service use (including length of psychiatric hospitalization [P < .0001], number of psychiatric admissions [P < .0001], and ER visits [P = .0006]) due to MDD diagnosis was significantly reduced. Subgrouping analysis for each SGA drug also showed significant reduction in number of psychiatric admissions for MDD patients who received aripiprazole (P < .0001), olanzapine (P = .003), quetiapine (P < .0001), and risperidone (P < .0001).
CONCLUSIONS: The study provides support that aripiprazole, olanzapine, quetiapine, and risperidone augmentation therapy could be effective in reducing psychiatric service utilization among MDD patients. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25295435     DOI: 10.4088/JCP.13m08843

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis.

Authors:  John Mark Franco; Saraschandra Vallabhajosyula; Timothy John Griffin
Journal:  BMJ Case Rep       Date:  2015-05-14

2.  A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression.

Authors:  Hiroko Sugawara; Kaoru Sakamoto; Tsuyoto Harada; Satoru Shimizu; Jun Ishigooka
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-10       Impact factor: 2.570

3.  The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

Authors:  Lucie Bartova; Gernot Fugger; Markus Dold; Alexander Kautzky; Marleen Margret Mignon Swoboda; Dan Rujescu; Joseph Zohar; Daniel Souery; Julien Mendlewicz; Stuart Montgomery; Chiara Fabbri; Alessandro Serretti; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.